Abstract
Patients with chronic kidney disease (CKD) have a high prevalence of atherosclerotic cardiovascular disease, likely reflecting the presence of traditional risk factors. A greater distinguishing feature of atherosclerotic cardiovascular disease in CKD is the severity of the disease, which is reflective of an increase in inflammatory mediators and vascular calcification secondary to hyperparathyroidism of renal origin that are unique to patients with CKD. Additional components of atherosclerotic cardiovascular disease that are prominent in patients with CKD include microvascular disease and myocardial fibrosis. Therapeutic interventions that minimize cardiovascular events related to atherosclerotic cardiovascular disease in patients with CKD, as determined by well-designed clinical trials, are limited to statins. Data are lacking regarding other available therapeutic measures primarily due to exclusion of patients with CKD from major trials studying cardiovascular disease. Data from well-designed randomized controlled trials are needed to guide clinicians who care for this high-risk population in the management of atherosclerotic cardiovascular disease to improve clinical outcomes.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 797-807 |
| Number of pages | 11 |
| Journal | Kidney international |
| Volume | 91 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 1 2017 |
Keywords
- atherosclerotic cardiovascular disease
- chronic kidney disease
- diagnosis
- medical management
- percutaneous coronary intervention
ASJC Scopus subject areas
- Nephrology